1
Total investments
1
Early stage
0
Mid stage
0
Late stage
11y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
2015
Avails Medical, Inc. is a pioneer in rapid, automated solutions for antibiotic susceptibility testing (AST). Founded by a team of Stanford postdoctoral researchers, Avails’ electronic biosensor technology is designed to improve affordability and speed in pathogen quantification and susceptibility testing directly from human specimens for clinical laboratories by eliminating manual, time-consuming culturing steps.
Avails’ eQUANT(TM) platform enables microbiology labs to generate an automated 0.5 McFarland equivalent (eMcF) directly from positive blood cultures (PBC), removing as many as 18+ hours from the standard workflow by eliminating the need for subcultures.
The eQUANT system is FDA 510(k) cleared.
IN DEVELOPMENT: Avails is also developing a rapid phenotypic AST platform being designed for use directly from PBCs as well as cultured isolates.
Avails electrical biosensor platform fits within the laboratorys existing workflow and budget, serving clinical labs in smaller community hospitals to larger academic centers and centralized laboratories.
Experience · 2 entries
All (2)
Investments (1)
Founder (1)
2015
Investor
2015
Avails Medical, Inc. is a pioneer in rapid, automated solutions for antibiotic susceptibility testing (AST). Founded by a team of Stanford postdoctoral researchers, Avails’ electronic biosensor technology is designed to improve affordability and speed in pathogen quantification and susceptibility testing directly from human specimens for clinical laboratories by eliminating manual, time-consuming culturing steps.
Avails’ eQUANT(TM) platform enables microbiology labs to generate an automated 0.5 McFarland equivalent (eMcF) directly from positive blood cultures (PBC), removing as many as 18+ hours from the standard workflow by eliminating the need for subcultures.
The eQUANT system is FDA 510(k) cleared.
IN DEVELOPMENT: Avails is also developing a rapid phenotypic AST platform being designed for use directly from PBCs as well as cultured isolates.
Avails electrical biosensor platform fits within the laboratorys existing workflow and budget, serving clinical labs in smaller community hospitals to larger academic centers and centralized laboratories.
1997
A
Asante Partners - Healthcare Investment Banking
Founder and Managing Director
1997
